We are live on ! Find out more
BLRX

BioLineRX
BLRX

24 hedge funds and large institutions have $5.65M invested in BioLineRX in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less funds holding

Funds holding: 26 → 24 (-2)

22% less capital invested

Capital invested by funds: $7.28M → $5.65M (-$1.63M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
24
Holders Change
-2
Holders Change %
-7.69%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$48.1K
2
UBS Group
UBS Group
Switzerland
+$31.9K
3
ARTA
A.R.T. Advisors
New York
+$24.1K
4
CCB
Cutter & Co Brokerage
Missouri
+$23.5K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$11.8K

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$99K
2
Millennium Management
Millennium Management
New York
-$69.9K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$40K
4
PAG
Private Advisor Group
New Jersey
-$15K
5
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Senvest Management
New York
$2.83M – – –
O
2
OrbiMed
New York
$831K – – –
Alyeska Investment Group
3
Alyeska Investment Group
Illinois
$490K +$11.8K +21 +2%
Morgan Stanley
4
Morgan Stanley
New York
$387K +$48.1K +86 +12%
Millennium Management
5
Millennium Management
New York
$340K -$69.9K -125 -15%
OM
6
Opaleye Management
Massachusetts
$223K – – –
Deutsche Bank
7
Deutsche Bank
Germany
$194K – – –
MC
8
Menta Capital
California
$79K -$560 -1 -0.6%
BCA
9
Benchmark Capital Advisors
New York
$35K -$2.8K -5 -6%
LTFS
10
Ladenburg Thalmann Financial Services
Florida
$32K – – –
NFG
11
Next Financial Group
Texas
$31K – – –
UBS Group
12
UBS Group
Switzerland
$29K +$31.9K +57 +1,900%
VKH
13
Virtu KCG Holdings
New York
$24K -$99K -177 -78%
CCB
14
Cutter & Co Brokerage
Missouri
$20K +$23.5K +42 New
ARTA
15
A.R.T. Advisors
New York
$20K +$24.1K +43 New
Commonwealth Equity Services
16
Commonwealth Equity Services
Massachusetts
$18K – – –
TSS
17
Two Sigma Securities
New York
$14K -$2.24K -4 -12%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$14K – – –
Bank of America
19
Bank of America
North Carolina
$13K – – –
Creative Planning
20
Creative Planning
Kansas
$12K – – –
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$4K – – –
KF
22
Krilogy Financial
Missouri
$1K – – –
WCM
23
Wealthcare Capital Management
Virginia
$1K – – –
Wells Fargo
24
Wells Fargo
California
$1K – – –
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
– -$40K -65 Closed
1
2

BLRX Hedge Fund Activity: Q2 2016 in Review

24 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2016, worth a combined $5.65M — down 22% from $7.28M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BLRX and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was Morgan Stanley, adding an estimated $48.1K. The largest seller was Virtu KCG Holdings, cutting an estimated $99K.

  • 24 institutional investors held BioLineRX (BLRX) as of Q2 2016, down from 26 in Q1 2016.
  • Funds reported $5.65M of BioLineRX stock for Q2 2016, down 22% quarter-over-quarter.
  • 2 funds opened new BioLineRX positions in Q2 2016 and 4 closed out, a net change of -2 holders.
  • The largest BioLineRX buyer in Q2 2016 was Morgan Stanley, an estimated $48.1K added.
  • The largest BioLineRX seller in Q2 2016 was Virtu KCG Holdings, an estimated $99K sold.

Based on aggregated 13F filings for Q2 2016.